Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jstrokecerebrovasdis.2020.104982 http://scihub22266oqcxt.onion/10.1016/j.jstrokecerebrovasdis.2020.104982 32689586!7245224!32689586     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Stroke+Cerebrovasc+Dis 2020 ; 29 (8): 104982 Nephropedia Template TP {{tp|p=32689586|t=2020. Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban |pdf=|usr=}}{{32689586}} gab.com Text Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban JO: J Stroke Cerebrovasc Dis http://www.kidney.de/pget.php?&tw=1&pmid=32689586 #FOAvip We report a case of ophthalmic artery occlusion (OAO) in a young patient with COVID-19 infection that was on therapeutic anticoagulation with apixaban for deep venous thrombosis (DVT). A 48-year-old man with obesity was hospitalized with a severe form of COVID-19 infection, complicated with acute respiratory failure, septic shock, dilated cardiomyopathy and fungemia. Despite treatment with prophylactic enoxaparin (initial D-Dimer 1.14 microg/ml FEU (normal < 0.05 microg/ml FEU), D-Dimer increased to above 20 microg/ml FEU and patient continued to spike high fevers. This prompted further investigations and upper and lower extremities DVTs were confirmed and managed with enoxaparin 1 mg/kg twice daily. D-dimer level decreased to 4.98 microg/ml FEU while on therapeutic anticoagulation. Three weeks later pending hospital discharge, the anticoagulation was switched to oral apixaban 10 mg twice daily. Patient developed acute severe right eye visual loss of no light perception and was diagnosed with incomplete OAO. D-Dimer was elevated at 2.13 microg/ml FEU. Stroke etiological work-up found no embolic sources, resolution of the dilated cardiomyopathy and negative antiphospholipid antibodies. Treatment was changed to enoxaparin and no thrombotic events were encountered to date. Ocular vascular complications have not yet been reported in COVID-19. Controversy exists on the best management algorithm for the hypercoagulable state associated to COVID-19 Either direct oral anticoagulants or low-molecular-weight-heparin are considered appropriate at discharge for patients with venous thromboembolism. The optimum regimen for ischemic stroke prevention and the significance of D-Dimer for anticoagulation monitoring in COVID-19 remain unclear. Twit Text FOAVip Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban ????J Stroke Cerebrovasc Dis http://www.kidney.de/pget.php?&tw=1&pmid=32689586 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32689586 #FOAvip English Wikipedia <ref>{{Cite pmid|32689586}}</ref> Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban #MMPMID32689586 Dumitrascu OM; Volod O; Bose S; Wang Y; Biousse V; Lyden PD J Stroke Cerebrovasc Dis 2020[Aug]; 29 (8): 104982 PMID32689586show ga We report a case of ophthalmic artery occlusion (OAO) in a young patient with COVID-19 infection that was on therapeutic anticoagulation with apixaban for deep venous thrombosis (DVT). A 48-year-old man with obesity was hospitalized with a severe form of COVID-19 infection, complicated with acute respiratory failure, septic shock, dilated cardiomyopathy and fungemia. Despite treatment with prophylactic enoxaparin (initial D-Dimer 1.14 microg/ml FEU (normal < 0.05 microg/ml FEU), D-Dimer increased to above 20 microg/ml FEU and patient continued to spike high fevers. This prompted further investigations and upper and lower extremities DVTs were confirmed and managed with enoxaparin 1 mg/kg twice daily. D-dimer level decreased to 4.98 microg/ml FEU while on therapeutic anticoagulation. Three weeks later pending hospital discharge, the anticoagulation was switched to oral apixaban 10 mg twice daily. Patient developed acute severe right eye visual loss of no light perception and was diagnosed with incomplete OAO. D-Dimer was elevated at 2.13 microg/ml FEU. Stroke etiological work-up found no embolic sources, resolution of the dilated cardiomyopathy and negative antiphospholipid antibodies. Treatment was changed to enoxaparin and no thrombotic events were encountered to date. Ocular vascular complications have not yet been reported in COVID-19. Controversy exists on the best management algorithm for the hypercoagulable state associated to COVID-19 Either direct oral anticoagulants or low-molecular-weight-heparin are considered appropriate at discharge for patients with venous thromboembolism. The optimum regimen for ischemic stroke prevention and the significance of D-Dimer for anticoagulation monitoring in COVID-19 remain unclear. |*Ophthalmic Artery/diagnostic imaging[MESH] |Arterial Occlusive Diseases/diagnostic imaging/*etiology[MESH] |Betacoronavirus/pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/blood/diagnosis/*drug therapy/virology[MESH] |Drug Substitution[MESH] |Enoxaparin/administration & dosage[MESH] |Factor Xa Inhibitors/*administration & dosage/adverse effects[MESH] |Host Microbial Interactions[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/diagnosis/*drug therapy/virology[MESH] |Pyrazoles/*administration & dosage/adverse effects[MESH] |Pyridones/*administration & dosage/adverse effects[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Treatment Outcome[MESH]Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban (epmc).pdf DeepDyve Pubget Overpricing